Phillip Wong

14PUBLICATIONS
204CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Infant and child healthPredictive and prognostic markersInnate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Oct 07, 2026
Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial.

|Jun 30, 2026
Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG.

|Feb 12, 2026
Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.

Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand

|Feb 02, 2026
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.

Brendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran

|Dec 01, 2025
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.

Evan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar

|Aug 27, 2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.

Apostolia M Tsimberidou, Farah A Alayli, Kwame Okrah

Pageof 3

Frequent Collaborators

6 joint publications

Matthew J Adamow

5 joint publications

Taha Merghoub

4 joint publications

Jedd D Wolchok

3 joint publications

Ronglai Shen